Targeting Genome Maintenance Defects of Cancers Using Chain-Terminating Nucleoside Analogs.

Abstract excerpt

Conventional cancer therapies, including radiation therapy and chemotherapy, rely on inflicting DNA damage, yet they inevitably affect normal cells, leading to severe adverse effects. The advent of precision chemotherapy exploiting tumor-specific DNA repair defects has validated the effectiveness of this approach. The first successful example is PARP inhibitors, which selectively kill homologous recombination...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• DNA Damage
• DNA Repair
• DNA Replication
• Mutation
• Neoplasms